{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hc.talzenna:0 retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Ahc.talzenna%3A0",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.003575,
    "timestamp_received": "2026-04-06T14:52:11.073926+00:00Z",
    "timestamp_returned": "2026-04-06T14:52:11.077501+00:00Z",
    "trace_id": "6a288eb1-60df-4dc2-83c4-242cccf9897c"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-03-05"
  },
  "data": [
    {
      "id": "ind:hc.talzenna:0",
      "indication": "TALZENNA (talazoparib) is indicated as a monotherapy for the treatment of adult patients with a deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated human epidermal growth factor receptor 2 (HER2)-negative locally advanced (not amenable to curative radiation or surgery) or metastatic breast cancer, who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting, unless patients were inappropriate for these treatments.",
      "initial_approval_date": null,
      "initial_approval_url": null,
      "description": "Health Canada approved talazoparib as a monotherapy for the treatment of adult patients with a deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated human epidermal growth factor receptor 2 (HER2)-negative locally advanced (not amenable to curative radiation or surgery) or metastatic breast cancer, who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting, unless patients were inappropriate for these treatments.",
      "raw_biomarkers": "deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative",
      "raw_cancer_type": "locally advanced or metastatic breast cancer",
      "raw_therapeutics": "Talzenna (talazoparib)",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:hc.talzenna",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Talzenna (talazoparib) [product monograph]. HC.",
        "title": null,
        "aliases": [],
        "description": "Pfizer Canada ULC. Talzenna (talazoparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078463.PDF. Revised January 2025. Accessed June 2025.",
        "urls": [
          "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98204",
          "https://pdf.hres.ca/dpd_pm/00078463.PDF"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "hc",
              "type": "Agent",
              "agentType": "organization",
              "name": "Health Canada",
              "description": "Regulatory agency that approves drugs for sale and use in Canada.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2025-06-11",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://health-products.canada.ca/dpd-bdpp/",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "Pfizer Canada ULC",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": "Talzenna",
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": "talazoparib",
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": "2020-09-30",
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": null,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2025-01-30",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}